3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
30
Nivolumab
10
Cyclophosphamide
9
fludarabine
7
atezolizumab
7
aldesleukin
5
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
5
Carboplatin
5
Biopsy
5
cemiplimab
4
Trastuzumab
4
Interleukin-2
4
Docetaxel
4
Cisplatin
4
spartalizumab
3
durvalumab
3
Specimen Handling
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Fulvestrant
3
Fluorouracil
3
tisotumab vedotin
2
tislelizumab
2
palbociclib
2
fludarabine phosphate
2
entinostat
2
avelumab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
bemarituzumab
×
Head & Neck
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled